PT  - JOURNAL ARTICLE
AU  - Li, Shilong
AU  - Sarangarajan, Rangaprasad
AU  - Jun, Tomi
AU  - Kao, Yu-Han
AU  - Wang, Zichen
AU  - Schadt, Emilio
AU  - Kiebish, Michael A.
AU  - Granger, Elder
AU  - Narain, Niven R.
AU  - Chen, Rong
AU  - Schadt, Eric E.
AU  - Li, Li
TI  - Association of in-hospital use of ACE-I/ARB and COVID-19 outcomes in African American population
AID  - 10.1101/2021.04.14.21255443
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.14.21255443
4099  - http://medrxiv.org/content/early/2021/04/22/2021.04.14.21255443.short
4100  - http://medrxiv.org/content/early/2021/04/22/2021.04.14.21255443.full
AB  - Importance The ACE D allele is more prevalent among African Americans (AA) compared to other races/ethnicities and has previously been associated with severe COVID-19 pathogenesis through excessive ACE1 activity. ACE-I/ARBs may counteract this mechanism, but their association with COVID-19 outcomes has not been specifically tested in the AA population.Objectives To determine whether the use of ACE-I/ARBs is associated with COVID-19 in-hospital mortality in AA compared with non-AA population.Design, Setting, and Participants In this observational, retrospective study, patient-level data were extracted from the Mount Sinai Health System’s (MSHS) electronic medical record (EMR) database, and 6,218 patients with a laboratory-confirmed COVID-19 diagnosis from February 24 to May 31, 2020 were identified as ACE-I/ARB users.Exposures Patients with an active prescription from January 1, 2019 up to the date of admission for ACE-I/ARB (outpatient use) and patients administered ACE-I/ARB during hospitalization (in-hospital use) were identified.Main Outcomes and Measures The primary outcome was in-hospital mortality, assessed in the entire, AA, and non-AA population.Results Of the 6,218 COVID-19 patients, 1,138 (18.3%) were ACE-I/ARB users. In a multivariate logistic regression model, ACE-I/ARB use was independently associated with reduced risk of in-hospital mortality in the entire population (OR, 0.655; 95% CI, 0.505-0.850; P=0.001), AA population (OR, 0.44; 95% CI, 0.249-0.779; P=0.005), and non-AA population (OR, 0.748, 95% CI, 0.553-1.012, P=0.06). In the AA population, in-hospital use of ACE-I/ARBs was associated with improved mortality (OR, 0.378; 95% CI, 0.188-0.766; P=0.006) while outpatient use was not (OR, 0.889; 95% CI, 0.375-2.158; P=0.812). When analyzing each medication class separately, ARB in-hospital use was significantly associated with reduced in-hospital mortality in the AA population (OR, 0.196; 95% CI, 0.074-0.516; P=0.001), while ACE-I use was not associated with impact on mortality in any population.Conclusion and Relevance In-hospital use of ARBs was associated with a significant reduction in in-hospital mortality among COVID-19-positive AA patients. These results support further investigation of ARBs to improve outcomes in AA patients at high risk for COVID-19-related mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors do not receive any external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Mount Sinai institutional review board (IRB): IRB-17-01245.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Mount Sinai Health System database is not publicly available. We utilized Python and R, and their open-source libraries to conduct our analysis tailored to MSH data. The code is available upon request.